



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

March 2, 2021

To, The Manager <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code – 532523</b>	To, The Manager <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - Biocon</b>
--	---

**Subject: Press Release titled “Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets”.**

Dear Sir/Madam,

Please find enclosed the press release titled “**Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets**”.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**



**Mayank Verma**  
Company Secretary and Compliance Officer

PRESS RELEASE

## **Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets**

***Bengaluru, India; March 2, 2021:***

**Biocon Biologics Ltd.**, a fully integrated ‘pure play’ biosimilars company and a subsidiary of **Biocon Ltd. (BSE code: 532523, NSE: BIOCON)**, announced today that **Mr Susheel Umesh** has joined Biocon Biologics as the Chief Commercial Officer - Emerging Markets (CCO-EMs) w.e.f. March 1, 2021. He will drive the company’s business in the Emerging Markets (EMs) and will also be responsible for the Branded Formulations business.

Susheel has over 30 years of experience in the pharmaceuticals industry, having worked in India, France and Sub-Saharan Africa for leading global pharma companies. He has managed global brands as well as led different functions in India and overseas in Sales & Marketing, Business Development and Operations Excellence. Most recently, he led the domestic formulations of an Indian biotech company as its Chief Executive Officer.

His expertise in building businesses based on patient centricity, ethics and business integrity makes him a perfect fit for Biocon Biologics’ Emerging Markets business at a time when the company is setting up a direct commercial presence in many of these markets to cater to the rapidly increasing demand for biosimilars.

With this appointment, Biocon Biologics will move its commercial operations from Singapore to its headquarters in Bengaluru.

**Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics**, said: *“We are very happy to welcome Susheel Umesh to Biocon Biologics. As Chief Commercial Officer, Susheel will be responsible for driving the company’s growth strategy in Emerging Markets on a platform of affordable access. With Dr Arun Chandavarkar taking over as Managing Director of Biocon Biologics, Shreehas Tambe as Deputy CEO and Susheel as CCO, I believe we now have a strong leadership team to drive the future growth of our biosimilars business. Biocon Biologics is built on strong business fundamentals and the biosimilars market remains a large addressable opportunity. I am confident of returning the company to its high growth trajectory soon.”*

**Dr Arun Chandavarkar, Managing Director, Biocon Biologics** said: *“We are extremely delighted to have Susheel Umesh lead our Commercial Operations for the Emerging Markets.*

*Susheel has deep expertise in diverse therapy areas, including Diabetes, Oncology, Cardiology and Transplantation, and has a proven track record of delivering robust business growth. In his role as Chief Commercial Officer, Susheel will drive Biocon Biologics' strategy for unlocking business opportunities in Emerging Markets, where we are ramping up our presence. Susheel's demonstrated leadership skills in building winning teams to deliver exceptional results through innovative and ethical practices, will go a long way in making Biocon Biologics a global leader."*

**Susheel Umesh, Chief Commercial Officer-Emerging Markets, said:** *"I am extremely proud to join Biocon Biologics, at this juncture where it has established a strong biosimilars business in global markets in collaboration with its partners. I believe the company is well-positioned to impact millions of patients globally, capitalizing on its strengths in science and global scale manufacturing expertise. In my role as Chief Commercial Officer of Emerging Markets, I look forward to scaling up the Company's business in emerging markets, expanding its footprint, as well as strengthening the patient-centric business environment. Together we stay committed to enable affordable access to patients, lower treatment costs for healthcare systems and improve overall healthcare outcomes. "*

Biocon Biologics has the scientific expertise and manufacturing scale to deliver complex biosimilars to patients across the globe. Its strong portfolio of in-market and in-development biosimilars covering Oncology, Diabetes, Immunology and other therapeutic areas, offer one of the industry's largest and most diverse global biosimilars pipelines. Biocon Biologics, has a footprint in the majority of the top 20 Emerging Markets and will be a meaningful contributor to the company's sustained growth.

**About Biocon Biologics Limited:**

**Biocon Biologics Limited**, a subsidiary of Biocon Limited is uniquely positioned as a fully integrated 'pure play' biosimilars organization in the world. Building on the four pillars of Patients, People, Partners and Business, Biocon Biologics is committed to transforming healthcare and transforming lives. Biocon Biologics is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. Five molecules from Biocon Biologics' portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan. With a team of over 4,800 people Biocon Biologics aspires to transform healthcare through affordable innovative solutions as well as impact millions of patients' lives. [Biocon Biologics on the Web](#) ; **Follow-us on Twitter:** [@BioconBiologics](#)



**About Biocon Limited:**

**Biocon Limited**, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. **Website: [www.biocon.com](http://www.biocon.com); Follow-us on Twitter: [@bioconlimited](https://twitter.com/bioconlimited)**

FOR MORE INFORMATION	
<b>MEDIA RELATIONS</b> <b>Seema Ahuja</b> Sr. VP & Global Head of Communications & Corporate Brand <b>Biocon Group &amp; Biocon Biologics</b> ☎ +91 80 2808 2222 📠 +91 99723 17792 ✉ <a href="mailto:seema.ahuja@biocon.com">seema.ahuja@biocon.com</a>	<b>INVESTOR RELATIONS</b> <b>Nikunj Mall</b> Head, Investor Relations, <b>Biocon Biologics</b> ☎ +91 80 6775 2040 📠 +91 99877 74078 ✉ <a href="mailto:nikunj.mall@biocon.com">nikunj.mall@biocon.com</a>

**Forward-Looking Statement: Biocon**

*This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon Limited, Biocon Biologics Limited and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon Limited, nor Biocon Biologics Limited, nor its Directors, nor any of its subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release*